AR018139A1 - Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento. - Google Patents

Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento.

Info

Publication number
AR018139A1
AR018139A1 ARP990100880A ARP990100880A AR018139A1 AR 018139 A1 AR018139 A1 AR 018139A1 AR P990100880 A ARP990100880 A AR P990100880A AR P990100880 A ARP990100880 A AR P990100880A AR 018139 A1 AR018139 A1 AR 018139A1
Authority
AR
Argentina
Prior art keywords
hidroxi
halo
manufacture
same
glici
Prior art date
Application number
ARP990100880A
Other languages
English (en)
Spanish (es)
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of AR018139A1 publication Critical patent/AR018139A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP990100880A 1998-03-04 1999-03-02 Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento. AR018139A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3427098A 1998-03-04 1998-03-04

Publications (1)

Publication Number Publication Date
AR018139A1 true AR018139A1 (es) 2001-10-31

Family

ID=21875345

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100880A AR018139A1 (es) 1998-03-04 1999-03-02 Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento.

Country Status (29)

Country Link
EP (1) EP1060164A1 (zh)
JP (1) JP2002505323A (zh)
KR (1) KR20010041584A (zh)
CN (1) CN1214011C (zh)
AP (1) AP1244A (zh)
AR (1) AR018139A1 (zh)
AU (1) AU753230B2 (zh)
BG (1) BG104740A (zh)
BR (1) BR9908470A (zh)
CA (1) CA2322207A1 (zh)
EA (1) EA200000804A1 (zh)
EE (1) EE200000506A (zh)
GE (1) GEP20033118B (zh)
HR (1) HRP20000574A2 (zh)
HU (1) HUP0100865A3 (zh)
ID (1) ID25591A (zh)
IL (1) IL137653A0 (zh)
IS (1) IS5582A (zh)
MY (1) MY123908A (zh)
NO (1) NO315703B1 (zh)
NZ (1) NZ506598A (zh)
OA (1) OA11530A (zh)
PL (1) PL342726A1 (zh)
SK (1) SK13002000A3 (zh)
TR (1) TR200002542T2 (zh)
UA (1) UA71906C2 (zh)
WO (1) WO1999044994A1 (zh)
YU (1) YU52000A (zh)
ZA (1) ZA994406B (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
WO2001079173A2 (en) 2000-04-17 2001-10-25 Celltech R & D Limited Enamine derivatives as cell adhesion molecules
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6921767B2 (en) * 2000-06-15 2005-07-26 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
EP1305291A1 (en) 2000-08-02 2003-05-02 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
AU2003299600A1 (en) * 2002-12-20 2004-07-29 Pharmacia Corpration The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
CA2612979A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. Parp modulators and treatment of cancer
JP2010520238A (ja) 2007-03-01 2010-06-10 マリンクロット インコーポレイテッド 統合された光活性低分子および統合された光活性低分子使用
JP4792124B1 (ja) * 2010-11-15 2011-10-12 エフイートレード株式会社 車両用保護フィルムの型取り方法、及び、車両用保護フィルムの製造方法
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
CA2878469A1 (en) 2012-07-18 2014-01-23 Saint Louis University Beta amino acid derivatives as integrin antagonists
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
EP3151670B1 (en) * 2014-06-04 2019-10-02 Monsanto Technology LLC 3,6-dichlorosalicylic acid compounds and related synthetic processes
ES2806276T3 (es) 2015-12-30 2021-02-17 Univ Saint Louis Derivados de ácido aminobenzoico meta-azaciclicos como antagonistas pan-integrina
JPWO2021230325A1 (zh) 2020-05-14 2021-11-18
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2230209A1 (en) * 1995-08-30 1997-03-06 G.D. Searle & Co. Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists

Also Published As

Publication number Publication date
NO315703B1 (no) 2003-10-13
NO20004316L (no) 2000-11-06
JP2002505323A (ja) 2002-02-19
TR200002542T2 (tr) 2001-05-21
EE200000506A (et) 2002-04-15
KR20010041584A (ko) 2001-05-25
MY123908A (en) 2006-06-30
HUP0100865A2 (hu) 2001-08-28
NZ506598A (en) 2003-07-25
IS5582A (is) 2000-08-04
CN1214011C (zh) 2005-08-10
SK13002000A3 (sk) 2001-07-10
ID25591A (id) 2000-10-19
BG104740A (en) 2001-02-28
IL137653A0 (en) 2001-10-31
WO1999044994A1 (en) 1999-09-10
AU3294799A (en) 1999-09-20
HRP20000574A2 (en) 2001-08-31
AU753230B2 (en) 2002-10-10
GEP20033118B (en) 2003-11-25
EA200000804A1 (ru) 2001-04-23
NO20004316D0 (no) 2000-08-30
ZA994406B (en) 2000-02-11
CA2322207A1 (en) 1999-09-10
EP1060164A1 (en) 2000-12-20
BR9908470A (pt) 2000-12-05
AP1244A (en) 2004-02-04
HUP0100865A3 (en) 2001-11-28
AP2000001893A0 (en) 2000-09-30
PL342726A1 (en) 2001-07-02
CN1291978A (zh) 2001-04-18
UA71906C2 (en) 2005-01-17
OA11530A (en) 2004-05-17
YU52000A (sh) 2003-02-28

Similar Documents

Publication Publication Date Title
AR018139A1 (es) Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento.
ECSP034732A (es) Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias
PA8547701A1 (es) Nucleosidos 4 substituidos.
DE60330910D1 (de) Verbindungen mit selektiverinhibierender wirkung für gsk3
AR032877A1 (es) Inhibidores alquil c(1-6)-4-amino-azepan-3-onicos de proteasas, composiciones farmaceuticas que los comprenden, intermediarios utiles en la preparacion de tales compuestos, procedimiento para la sintesis de dichos inhibidores, y uso de dichos inhibidores en la fabricacion de medicamentos
AR026173A1 (es) Inhibidores de neuraminidasas.
ES2058527T3 (es) Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
AR009052A1 (es) Tienopirimidinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen y un procedimiento para obtener estas preparaciones farmaceuticas
BRPI0406717A (pt) Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção
ES2083359T3 (es) Piperidinas 1,4-substituidas como inhibidores de la acetilcolinesterasa y su utilizacion en el tratamiento de la enfermedad de alzheimer.
AR035792A1 (es) Compuestos de n-(4-quinazolinil)-n-(1h-indazol-5-il) amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y metodo para prepararlo
BR9908545A (pt) Derivado de piperidina, processo para a preparação do mesmo, composto, processo para a preparação do mesmo, e, composição farmacêutica
BR0113234A (pt) Polimorfos de um análogo de epotilona
UY26872A1 (es) Derivados de la 4- fenil piridina
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
ECSP034744A (es) Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos
ES2158778B1 (es) Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen.
AR029403A1 (es) Derivados n-sustituidos de carbamoiloxialquil-azolio,un proceso para su fabricacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento
AR003440A1 (es) Nuevos derivados de aminoacidos, formulacion farmaceutica que los contiene, uso de dichos derivados para preparar medicamentos y procedimiento para la preparacion de dichos derivados.
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
UY27700A1 (es) Compuestos oxo - azabiclícos.
AR004961A1 (es) Modificacion cristalina v del clorhidrato de(r)-(-)-2-{n-[4-(1,1-dioxido-3- oxo-2,3-dihidro-benzisotiazol-2-il)-butil]-aminometil)cromano, unprocedimiento para su preparacion, medicamentos que lo contienen, el uso de dicho clorhidrato para la preparacion de medicamentos, una composicion para el
UY27548A1 (es) Sales de ácido succínico de 5,7,14-triazatetraciclo (10.3.1.02.11.04,9) exadeca-2 (11),3,5,7,9-pentaeno y composiciones farmacéuticas
BR0207408A (pt) Azóis como inibidores de malonil-coa decarboxilase úteis como moduladores metabólicos
ES2038172T3 (es) Procedimiento para preparar carboxamidas heterociclicas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure